NanOlogy, LLC, a Texas-based, private clinical-stage oncology company, announced on Thursday that it has launched a drug development program aimed at transforming the treatment of diffuse intrinsic pontine glioma (DIPG), an aggressive, highly lethal paediatric brainstem tumour.

The company is developing Large Surface Area Microparticle (LSAM) Cisplatin for stereotactic intratumoral (IT) administration in this initial indication.

NanOlogy is completing Investigational New Drug (IND) enabling studies required by the US Food and Drug Administration (FDA). Upon completion of these studies, the company plans to submit an IND application for LSAM-Cisplatin to treat malignant neoplasms of the brain, including DIPG.

Subject to FDA approval to proceed, NanOlogy says that it aims to initiate a clinical trial in late 2026 to evaluate the safety and response of stereotactic IT administration of LSAM-Cisplatin in children diagnosed with DIPG.